Meiragtx Holdings Plc SEC Filings

MeiraGTx Holdings (MGTX) reported a wider quarterly loss and tighter liquidity. For the three months ended September 30, 2025, total revenue was $410 thousand versus $10.9 million a year ago, driven by lower related-party service revenue. Operating expenses were $46.5 million, leading to a loss from operations of $46.1 million and a net loss of $50.5 million (basic and diluted loss per share $0.62).

Cash and cash equivalents fell to $14.8 million from $103.7 million at year-end, and shareholders’ equity moved to a $(40.6) million deficit as accumulated deficit reached $831.3 million. The company used $93.0 million in operating cash in the first nine months.

Management highlights pending strategic funding: an expected $200 million upfront from Hologen in Q4 2025 (with $28.0 million received during the period and an additional $22.0 million deposit in Q4 to date), up to $230 million of additional Hologen funding, and a $75.0 million upfront from Eli Lilly. Together with tax incentives and receivables, these are expected to fund operations for at least twelve months. Ordinary shares outstanding were 80,490,889 as of October 28, 2025.

MeiraGTx (MGTX) announced a strategic collaboration and license with Eli Lilly focused on ophthalmology genetic medicines. MeiraGTx will receive an upfront payment of $75 million and is eligible for up to over $400 million in total milestone payments, including up to $135 million tied to development and regulatory milestones. Lilly receives exclusive, worldwide rights to develop and commercialize the AAV-AIPL1 program for LCA4 and two additional preclinical retinal candidates.

Lilly also receives exclusive licenses to proprietary intravitreal capsids and pan‑retinal/rod‑specific promoters for up to five ophthalmology targets each, plus a right of first designation on certain target-specific transactions and a right of first negotiation for MeiraGTx’s riboswitch technology in ophthalmological gene editing. Lilly will fund research, development and commercialization, and MeiraGTx Ocular will receive tiered royalties. The agreement includes standard IP ownership provisions and is terminable for uncured material breach; Lilly may also terminate in whole, by product, or by country with notice.

MeiraGTx Holdings plc (MGTX) reported an insider transaction: CFO & COO Richard Giroux sold 24,000 ordinary shares on Oct 21, 2025 at a $8.87 weighted average pursuant to a Rule 10b5-1 trading plan adopted Aug 29, 2024.

Sale prices ranged from $8.65 to $9.06. After the transaction, he beneficially owns 829,494 shares directly, plus 5,152 indirectly via spouse and 85,000 indirectly via Aigle Healthcare Partners III LLC.

Insider sale by a senior officer: Alexandria Forbes, listed as President & CEO and a director, reported a sale of 47,500 ordinary shares of MeiraGTx Holdings plc (MGTX) on 10/07/2025. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on 08/21/2024.

The filing shows a weighted average sales price of $8.39, with individual trade prices ranging from $8.23 to $8.53. Following the reported disposition, the reporting person beneficially owns 1,313,983 ordinary shares.

MeiraGTx Holdings (MGTX) filed a Form 144 notice for the proposed sale of 47,500 ordinary shares under Rule 144. The filing lists an aggregate market value of $398,525 and an approximate sale date of 10/07/2025. The broker named is Merrill Lynch, 200 Park Avenue, New York, NY 10166, and the shares are listed on NASDAQ.

The securities to be sold were acquired on 06/07/2018 via an incentive compensation stock grant from the issuer, with 47,500 shares acquired on that date. As context, the filing states 80,447,477 shares were outstanding.

MeiraGTx reported continued operating losses as it advances its gene-therapy pipeline and manufacturing business. For the six months ended June 30, 2025 the company recorded a $78.8 million net loss and used $80.8 million of cash from operations. Cash, cash equivalents and restricted cash totaled $34.4 million at June 30, 2025 and the balance sheet showed a $780.8 million accumulated deficit, leaving shareholders' equity at $3.0 million.

Strategically, MeiraGTx signed a March 9, 2025 collaboration with Hologen that contemplates a $200 million upfront payment and up to $230 million of additional funding; Hologen made a $6.0 million payment in June 2025 and an additional $17.0 million payment in the third quarter of 2025, and the parties expect the transaction to close in the third calendar quarter of 2025, subject to customary conditions. The company also retains a supply agreement and contingent payments tied to the prior asset sale to Johnson & Johnson (an initial $65.0 million upfront in 2023 and $60.0 million in milestones received in 2024, with up to $350.0 million of contingent consideration remaining). Management states available cash, receivables, the $17.0 million deposit received and anticipated remaining collaboration proceeds are expected to be sufficient to fund operations for at least the next twelve months.

MeiraGTx Holdings plc (MGTX) – Form 4 insider transaction

President & CEO Alexandria Forbes reported the sale of 47,500 ordinary shares of MGTX on 8 July 2025. The shares were disposed of at a weighted-average price of $7.97 per share (individual trade prices ranged from $7.73 to $8.15). The transaction was executed under a Rule 10b5-1 trading plan adopted 21 Aug 2024, indicating it was pre-scheduled and not the result of ad-hoc decision-making.

Following the sale, Forbes’ direct beneficial ownership stands at 1,361,483 ordinary shares. No derivative securities were involved in this filing, and no additional transactions were reported.

The gross proceeds of the reported sale, based on the disclosed weighted-average price, total roughly $379 thousand. Forbes continues to serve as both Director and President & CEO of MeiraGTx.